I was recently reviewing current clinical trials and came across this one for men who have failed chemotherapy, what many of us view as the final treatment for advanced prostate cancer. It provides a potential opportunity to combine two different therapy agents (one old, mitoxantrone; one relatively new, ixabepilone). Both of these chemicals are known to have activity in prostate cancer in vivo (not just in a petri dish or test tube).

The best I can tell is that this trial appears to be available only at the UCSF Helen Diller
Cancer Center at the National Cancer Institute (NCI). The clinicaltrial.gov identifier is NCT00331344.